Holen Sie sich die Stockscreener-App
29.05
0.21%
-0.06
Schlusskurs vom Vortag:
$29.11
Offen:
$28.83
24-Stunden-Volumen:
413.96K
Relative Volume:
0.60
Marktkapitalisierung:
$1.81B
Einnahmen:
$32.08M
Nettoeinkommen (Verlust:
$-169.77M
KGV:
-10.22
EPS:
-2.8418
Netto-Cashflow:
$-147.70M
1W Leistung:
-7.43%
1M Leistung:
-4.00%
6M Leistung:
+1.22%
1J Leistung:
+135.22%
1-Tages-Spanne:
$28.48
$29.49
1-Wochen-Bereich:
$28.35
$31.60
52-Wochen-Spanne:
$12.25
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
29.05 | 1.81B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Canada
Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat
Stoke Therapeutics Inc (STOK) - MSN
Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo
Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK
Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com Nigeria
Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma
Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com
Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com
Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire
STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa
Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review
Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - ad-hoc-news.de
Stoke Therapeutics holds the focus. Investors await the next evidence - ad-hoc-news.de
Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan
Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria
Stoke Therapeutics (STOK) Receives a Buy from Jefferies - The Globe and Mail
STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales - Stock Titan
Stoke Therapeutics (STOK) Edges Lower as Stock Consolidates Near Key LevelsETF Flow - dars.gov.et
Responsive Playbooks and the STOK Inflection - Stock Traders Daily
Stoke completes phase 3 enrollment for Dravet syndrome drug - Investing.com UK
Stoke completes Phase 3 enrollment for Dravet drug study - grafa.com
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - BioSpace
Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Stud - GuruFocus
Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment - Moomoo
Stoke Therapeutics (STOK) Advances Phase 3 Study and NDA Plans - GuruFocus
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial - TipRanks
Stoke completes phase 3 enrollment for Dravet syndrome drug By Investing.com - Investing.com Canada
Stoke CEO Ian Smith to speak April 14 at Needham healthcare event - Stock Titan
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027 - TradingView
Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA - Stock Titan
Dravet Syndrome Foundation (DSF) Announces 2026 Community Award Winners - EIN Presswire
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Index - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index - marketscreener.com
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)? - simplywall.st
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):